Skip to main content
MedPathMedPath Home
Clinical Trials/NL-OMON48173
NL-OMON48173
Recruiting
Phase 2

Track and treat in NSCLC (TATIN) - ctDNA guided treatment of early resistance to targeted treatment in patients with EGFR positive NSCLC - TATI

Antoni van Leeuwenhoek Ziekenhuis0 sites30 target enrollmentTBD
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit

Overview

Phase
Phase 2
Intervention
Not specified
Conditions
Not specified
Sponsor
Antoni van Leeuwenhoek Ziekenhuis
Enrollment
30
Status
Recruiting
Last Updated
2 years ago
OverviewInvestigatorsEligibility CriteriaOutcomesSimilar Trials

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
TBD
End Date
TBD
Last Updated
2 years ago
Study Type
Interventional

Investigators

Sponsor
Antoni van Leeuwenhoek Ziekenhuis

Eligibility Criteria

Inclusion Criteria

  • •1\. Histologically confirmed metastatic NSCLC, characterized by a sensitizing
  • •exon 19 deletion or exon 21 L858R EGFR mutation., 2\. WHO performance status
  • •0\-2\., 3\. Eligible for osimertinib treatment according to the label and
  • •according to the treating physician., 4\. Patients must be \>\=18 years of age.

Exclusion Criteria

  • •1\. Patients with symptomatic central nervous system metastases who are
  • •neurologically unstable. Unstable brain metastases except for those who have
  • •completed definitive therapy and have had a stable neurological status for 2
  • •weeks after completion of definitive therapy. Patients may be on
  • •corticosteroids to control brain metastases if they have been on a stable dose
  • •for 2 weeks prior to the start of study treatment and are clinically
  • •asymptomatic.

Outcomes

Primary Outcomes

Not specified

Similar Trials

Active, not recruiting
Phase 1
ctDNA guided treatment of early resistance to targeted treatmentPatients with histologically confirmed metastatic NSCLC, characterized by a sensitizing exon 19 deletion or exon 21 L858R EGFR mutation that are eligible for osimertinib treatment.MedDRA version: 20.0 Level: SOC Classification code 10029104 Term: Neoplasms benign, malignant and unspecified (incl cysts and polyps) System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)Therapeutic area: Diseases [C] - Cancer [C04]
EUCTR2018-004798-29-NLStichting Het Nederlands Kanker Instituut-Antoni van Leeuwenhoek Ziekenhuis30
Completed
Not Applicable
ctDNA Guided Treatment of Early Resistance to Targeted TreatmentCarcinoma, Non-Small-Cell Lung
NCT04148066The Netherlands Cancer Institute104
Active, not recruiting
Phase 1
A trial using ctDNA mutation tracking to detect cancer cells in the blood of patients with triple negative breast cancer who have completed standard treatmentEarly stage triple negative breast cancerMedDRA version: 20.0Level: PTClassification code 10006187Term: Breast cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)Therapeutic area: Diseases [C] - Cancer [C04]
EUCTR2017-000508-92-GBThe Institute of Cancer Research150
Unknown
Not Applicable
Recurrence Monitoring in NSCLC Using Circulating Tumor DNANon Small Cell Lung Cancer
NCT03878537Scripps Translational Science Institute50
Active, not recruiting
Not Applicable
A trial using blood tests to detect cancer cells after standard treatment to trigger additional treatment in early stage triple negative breast cancer patientsBreast cancerCancer
ISRCTN12569958Institute of Cancer Research208